Sexual Side-Effects of Psychiatric Drugs

1989 ◽  
Vol 18 (3) ◽  
pp. 243-252 ◽  
Author(s):  
R. T. Segraves
Keyword(s):  
Erectile Dysfunction ◽  
Side Effects ◽  
Monoamine Oxidase ◽  
Sexual Function ◽  
Clinical Case ◽  
Case Reports ◽  
Psychiatric Drugs ◽  
Sexual Side Effects ◽  
Clinical Series ◽  
Retarded Ejaculation

Clinical case reports, clinical series, and a small number of controlled studies provide evidence that many commonly prescribed psychiatric drugs may have untoward effects on sexual function. Both heterocyclic antidepressants and monoamine oxidase inhibitors appear to be associated with ejaculatory impairment. Erectile dysfunction and retarded ejaculation have been associated with neuroleptics. Several benzodiazepines have been reported to interfere with ejaculation. This information has clear significance for the prescribing physician.

Anorgasmia from Clomipramine in Obsessive-Compulsive Disorder

1987 ◽  
Vol 151 (1) ◽  
pp. 107-112 ◽  
Author(s):  
W. O. Monteiro ◽  
H. F. Noshirvani ◽  
I. M. Marks ◽  
P.T. Lelliott
Keyword(s):  
Side Effects ◽  
Sexual Function ◽  
Obsessive Compulsive Disorder ◽  
Structured Interview ◽  
Controlled Study ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Men And Women ◽  
Compulsive Disorder ◽  
Sexual Side Effects

Forty-six patients with obsessive-compulsive disorder undergoing a double-blind controlled study of clomipramine and placebo were interviewed to assess changes in sexual function. Of 33 patients with previously normal orgasm, nearly all of the 24 on clomipramine developed total or partial anorgasmia; none of the 9 on placebo did so. Anorgasmia persisted with minimal tolerance over the five months that clomipramine was taken. Men and women were equally affected. Sexual side-effects are easily missed without a structured interview, and can detract from the value of drug treatment.

Clinical case: Gynecological side effects caused by methylphenidate

2017 ◽  
Vol 41 (S1) ◽  
pp. S430-S430
Author(s):  
A. Ballesteros ◽  
Á.S. Rosero ◽  
F. Inchausti ◽  
E. Manrique ◽  
H. Sáiz ◽  
...  
Keyword(s):  
Side Effects ◽  
Attention Deficit Disorder ◽  
Clinical Case ◽  
Case Reports ◽  
Treatment Plan ◽  
Complete Recovery ◽  
Current Evidence ◽  
Drug Discontinuation ◽  
Pubmed Search ◽  
Competing Interest

IntroductionMethylphenidate drugs is prescribed in attention deficit disorder and hyperactivity. Among its rare side effects, include alterations in the gynecological. We report a clinical case and review current evidence regarding the tolerability this drug in this area.MethodsWe performed a PubMed search of articles published in English of different types (case reports or case/controls studies). We collected the clinical practice guidelines conclusions regarding adverse drug reactions.Case presentationOur patient is a 14-year-old male diagnosed of ADHD treated with methylphenidate (0.8–1 mg\kg). He developed bilateral and asymmetric gynecomastia under this treatment plan so a referral was made to rule out other causes of this event. After performing several work up tests, it was concluded that this clinical presentation was caused by methylphenidate. Hence, we initiated crossed titration swapping this drug to atomoxetine. Four months later, he was mentally stable and he experimented a volumetric decrease as concerns his gynecomastia.As regards methylphenidate, in 2009 a couple of cases in which alterations in the sexual sphere presented with the oros presentation were reported. There are series of reported pharmacological side effects (gynecomastia) and also denoted an improvement of the same months after drug discontinuation.ConclusionsGynecological clinic secondary to the use of psychotropic drugs in ADHD is uncommon. In line with our case, the current evidence suggests a drug suspension as adverse effects are usually reversible (although it may take several months to complete recovery). Further studies are needed to understand the mechanisms underlying these tolerability issues.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals The Potential of Hormonal Contraception to Influence Female Sexuality

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Filipa de Castro Coelho ◽  
Cremilda Barros
Keyword(s):  
Side Effects ◽  
Sexual Function ◽  
Female Sexuality ◽  
Hormonal Contraception ◽  
Narrative Review ◽  
Hormonal Contraceptives ◽  
Female Sexual Function ◽  
Sexual Side Effects ◽  
The Impact

The association between female sexual function and hormonal contraception is controversial. Recognition and management of sexual side effects in women using hormonal contraceptives are challenging. An unsatisfactory number of studies report the influence of the available contraceptives on female sexuality. This article provides an updated narrative review regarding the effect and the magnitude of the impact that hormonal contraceptives play in female sexual function.

Beneficial Sexual Side-effects from Fluoxetine

1994 ◽  
Vol 164 (2) ◽  
pp. 249-250 ◽  
Author(s):  
Parsley Power-Smith
Keyword(s):  
Side Effects ◽  
Beneficial Effect ◽  
Sexual Function ◽  
Premature Ejaculation ◽  
Sexual Side Effects ◽  
Therapeutic Doses

We report cases of several side-effects from the antidepressant fluoxetine. We suggest that, at therapeutic doses, fluoxetine may have a beneficial effect on sexual function in some men with erectile failure and premature ejaculation.

Sexual Problems and Cancer

2021 ◽  
pp. 276-282
Author(s):  
Jeanne Carter ◽  
Ashley Arkema ◽  
Andrew J. Roth ◽  
Sally Saban ◽  
Christian J. Nelson
Keyword(s):  
Side Effects ◽  
Sexual Health ◽  
Sexual Function ◽  
Cancer Survivors ◽  
Sexual Interest ◽  
Treatment Modalities ◽  
Long Term Effects ◽  
Referral Networks ◽  
Sexual Side Effects ◽  
Additional Support

Cancer survivors face a unique set of treatment-related issues impacting sexual function and quality of life. While some treatment-related sexual adverse effects are temporary, many survivors face long-term effects such as treatment-induced menopause, altered gonadal function, and significant surgical disfigurement. Treatment modalities including surgery, chemotherapy, radiation therapy, and endocrine therapy present with persistent changes in tissue quality and sexual response. Common changes in sexual function for cancer survivors include decreased libido or sexual interest and pain with penetration in women and erectile dysfunction in men. As cancer survivorship improves, it is increasingly important for medical professionals to inquire about the sexual health of their patients. Health promotion strategies such as vulvovaginal moisturizers and dilator therapy for women or prescription medication for men can be recommended to counteract sexual side effects during and after treatment. Additionally, sexual counseling can enhance communication among distressed couples coping with cancer. While sexual side effects are prevalent, they often go unacknowledged in busy clinical settings. Screening tools can be utilized to identify treatment-related complications including lymphedema, fatigue, insomnia, and pain. Standardized measures validated in cancer populations are recommended to clinicians assessing sexual dysfunction in oncologic settings. Educational resources and sexual health referral networks can provide additional support to help patients manage distressing symptoms.

Sexual Side-Effects of Contemporary Antidepressants: Review

2009 ◽  
Vol 43 (9) ◽  
pp. 795-808 ◽  
Author(s):  
Isaac Schweitzer ◽  
Kay Maguire ◽  
Chee Ng
Keyword(s):  
Major Depressive Disorder ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Depressive Disorder ◽  
Sexual Function ◽  
Rating Scales ◽  
Major Depressive ◽  
Double Blind ◽  
Direct Assessment ◽  
Sexual Side Effects

The aim of the present study was to review the sexual side-effects of contemporary antidepressants in Australia, comparing the selective serotonin re-uptake inhibitors (SSRIs) with venlafaxine, reboxetine, mirtazepine, duloxetine, bupropion, desvenlafaxine and agomelatine. Double-blind, randomized comparative studies of these antidepressants that included assessment of sexual dysfunction with validated rating scales in patients with major depressive disorder were identified from the literature using MEDLINE, EMBASE and PsychINFO databases. Bupropion and duloxetine caused significantly less sexual dysfunction than the SSRIs in short-term studies and reboxetine significantly less in both short- and longer term studies. Bupropion and agomelatine caused significantly less sexual dysfunction than venlafaxine. The evidence for mirtazepine having an advantage over the SSRIs is lacking and there are currently insufficient data for desvenlafaxine. Well-designed comparative studies of contemporary antidepressants with direct assessment of sexual side-effects as the primary outcome measure are scarce. Future studies should be randomized, double-blind, active controlled trials in sexually active subjects with major depressive disorder. There should be direct assessment of sexual function and depression using reliable, validated rating scales before and during treatment. Studies should assess treatment-emergent effects in patients with normal function and resolution of baseline dysfunction over treatment, in both the short and long term. Further research should compare available instruments for measuring sexual function, and include separate analyses of both remitters/non-remitters and male/female subjects.

scholarly journals Sexual side-effects of antidepressant and antipsychotic drugs

2003 ◽  
Vol 9 (3) ◽  
pp. 202-210 ◽  
Author(s):  
David Baldwin ◽  
Andrew Mayers
Keyword(s):  
Side Effects ◽  
Sexual Dysfunction ◽  
Adverse Effects ◽  
Sexual Function ◽  
Psychotropic Drugs ◽  
Antipsychotic Drugs ◽  
Well Being ◽  
Sexual Expression ◽  
Human Relationships ◽  
Sexual Side Effects

Adequate sexual expression is essential to many human relationships and provides a sense of physical, psychological and social well-being. Epidemiological and clinical studies show that depression and schizophrenia are associated with impairment of sexual function and satisfaction, even in untreated patients. Most antidepressant and antipsychotic drugs have adverse sexual effects but it is difficult accurately to identify the incidence of treatment-emergent dysfunction, as disturbances can be reliably detected only from systematic enquiries made at baseline and during treatment. Growing awareness of the adverse effects of psychotropic drugs has led to attempts to use adjuvants or substitute treatments to resolve sexual dysfunction. More studies of the effects of antidepressant and antipsychotic drugs on sexual function are needed.

Erectile dysfunction and antipsychotics

2011 ◽  
Vol 26 (S2) ◽  
pp. 1543-1543
Author(s):  
F. Fifani ◽  
Y. Otheman ◽  
M. Outarahout ◽  
A. Ouanass
Keyword(s):  
Quality Of Life ◽  
Erectile Dysfunction ◽  
Side Effects ◽  
Sexual Dysfunction ◽  
Fluphenazine Decanoate ◽  
Antipsychotic Medications ◽  
Sexual Side Effects ◽  
Male Patients ◽  
Classification Evaluation

Sexual side effects associated with antipsychotic medications constitute an understudied set of side effects that diminish a patient's quality of life, and lead to noncompliance with treatment. Male patients frequently report disturbances in erectile and ejaculatory functioning, as well as changes in libido. The capacity to trigger sexual dysfunction differs from one antipsychotic to another. Clinicians prescribing antipsychotic medications should be familiar with the classification, evaluation and treatment of these side effects. The purpose of this study is to assess the occurrence of erectile dysfunction for 5 classes of antipsychotics (Haloperidol, Risperidone, Olanzapine, Amisulpride and Fluphenazine decanoate) in a population of 120 patients, using the International Index of Erectile Dysfunction (IIEF 5).

Sign in / Sign up

Export Citation Format

Share Document